Lenalidomide plus dexamethasone as first-line therapy in transplant-ineligible patients with multiple myeloma: Final results of the prospective, non-interventional study FIRST-NIS and comparison with the FIRST pivotal phase III clinical trial.

10. August 2026

Nückel H, Behlendorf T, Schulz H, Schulze M, Schardt C, Medinger T, Koenigsmann M, Dechow T, Indorf M, Bürkle D, Engelbertz V1, Rauh J11, Schmidt B1, Sauer A1, Vannier C, Potthoff K.

Cancer Medicine 15, no. 4 (2026): e71758

Abstract